Nevertheless, the pooled analysis of the misregulation of all targets of TP53 across all tumor types reveals that although in most cases truncating mutation of the TF do affect more the expression of its targets than missense mutations, the differences are clearly significant only in breast tumors, glioblastomas, and low grade gliomas (Additional file 1: Figure S4). The gene discussed is TP53; the disease is breast neoplasm.